FPR2 and scleroderma: However, WKYMVm treatment did not directly affect TGF-β1-induced differentiation of fibroblasts to α-SMA-positive myofibroblasts, suggesting that WKYMVm-induced activation of Fpr2 indirectly alleviates myofibroblast differentiation in the BLM-induced scleroderma model.